Tagged: hybrid business models in pharma

The pharmaceutical sector’s performance has surprised many experts. The PwC pharma index delivered just 7.6% returns to shareholders since 2018, while the S&P 500 achieved 15%. This gap grew more pronounced last year when pharma returns reached 13.9% compared to the broader market’s 28.7%. Today’s...